Clinical trial NCT00033553 (phase 2, status: completed)
Conditions: lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: carboplatin, gemcitabine hydrochloride, paclitaxel
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)

               -  Squamous cell carcinoma

               -  Adenocarcinoma, including bronchoalveolar cell carcinoma

               -  Large cell anaplastic carcinoma, including giant and clear cell carcinoma

          -  Inoperable stage IIIA or IIIB disease

          -  No direct invasion of vertebral body

               -  Tumors adjacent to a vertebral body without bone invasion allowed if all gross
                  disease can be encompassed in radiotherapy boost field

          -  Contralateral mediastinal disease (N3) allowed if all gross disease can be encompassed
             in radiotherapy boost field

          -  No scalene, supraclavicular, or contralateral hilar node involvement

          -  Transudate, cytologically negative, non-bloody pleural effusion allowed if it can be
             encompassed in radiotherapy field

               -  No exudative, bloody, or cytologically malignant pleural effusion

               -  Evidence of pleural effusion by chest CT scan but not chest x-ray that is too
                  small to tap allowed

          -  At least 1 unidimensionally measurable lesion

               -  At least 20 mm by conventional techniques OR

               -  At least 10 mm by spiral CT scan

               -  The following are not considered measurable disease:

                    -  Bone lesions

                    -  Leptomeningeal disease

                    -  Ascites

                    -  Pleural/pericardial effusion

                    -  Abdominal masses that are not confirmed and followed by imaging techniques

                    -  Cystic lesions

                    -  Tumor lesions in a previously irradiated field

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  ECOG 0-1

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Granulocyte count at least 1,500/mm3

          -  Platelet count at least 100,000/mm3

        Hepatic:

          -  Bilirubin less than 1.5 mg/dL

          -  AST less than 2 times upper limit of normal

        Renal:

          -  Creatinine clearance 20-130 mL/min for females

          -  Creatinine clearance 20-150 mL/min for males

        Pulmonary:

          -  FEV1 at least 1.2 L

        Other:

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  No other currently active malignancy (defined as completed prior therapy and
             considered to be at less than 30% risk of relapse) except non-melanoma skin cancer

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  No prior chemotherapy for NSCLC

          -  No other concurrent chemotherapy

        Endocrine therapy:

          -  No concurrent hormonal therapy except steroids for adrenal failure or septic shock,
             hormones for non-disease-related conditions (e.g., insulin for diabetes), or
             glucocorticosteroids as antiemetics

        Radiotherapy:

          -  See Disease Characteristics

          -  No prior radiotherapy for NSCLC

        Surgery:

          -  At least 2 weeks since prior exploratory thoracotomy